|
HNSP has a broad range of products including: 13 peptides at different stages of development: four peptide intermediates shipped to U.S. clients 23 small-molecule drug products in 36 strengths: Approved by NMPA, U.S. FDA, SFDA, KSA, TGA Leading HNSP products currently include: |
|
Paclitaxel (Albumin bound)
100 mg
Lyophilized Powder
|
Bivalirudin for Injection
250mg
Lyophilized Powder
|
|
Eptifibatide Injection
20mg/10mL, 75 mg/100 mL
Injection
|
Octreotide Acetate Injection
0.1 mg/mL
Injection
|
|
Bortezomib for Injection
3.5 mg/vial
Lyophilized Powder
|
Vasopressin Injection
20 units/mL
Injection
|
|
Pantoprazole Sodium for Injection
40 mg
Lyophilized Powder
|
Lanreotide (long-acting)
60mg/0.2mL, 90mg/0.3mL, 120mg/0.5mL
/
|
|
Semaglutide
2MG/1.5ML (1.34MG/ML)
4MG/3ML (1.34MG/ML)
8MG/3ML (2.68MG/ML)
2MG/3ML (0.68MG/ML)
1.7MG/0.75ML (1.7MG/0.75ML)
2.4MG/0.75ML (2.4MG/0.75ML)
Injection
|
Tirzepatide
2.5MG/0.5ML (2.5MG/0.5ML)
5MG/0.5ML (5MG/0.5ML)
7.5MG/0.5ML (7.5MG/0.5ML)
10MG/0.5ML (10MG/0.5ML)
12.5MG/0.5ML (12.5MG/0.5ML)
15MG/0.5ML (15MG/0.5ML)
Injection
|
|
Goserelin
3.6mg, 10.8mg
Implant
|
Linaclotide
72mg 145mg, 290mg
Capsule
|
|
SCB107-LR (long-acting)
42 mg
kit
|
SCB101-DD (long-acting)
80mg, 120mg
Vial
|
|
SCB103-QT (long-acting)
3.75mg, 11.25mg, 22.5 mg
Vial
|
SCB104-OA (long-acting)
/
/
|
